Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-Mesitran is a medical-grade honey (MGH) based wound care product line. It contains 40% medical grade honey supplemented with other ingredients such as vitamins C and E, lanolin, PEG4000, and propylene glycol to enhance its antimicrobial and wound healing properties. The product works through multiple mechanisms including osmotic activity, low pH, release of hydrogen peroxide, and the presence of antimicrobial molecules. When applied to wounds, it draws fluid from surrounding tissues through osmosis, creating a moist wound healing environment that stimulates the healing process, aids in wound bed preparation, facilitates autolysis of necrotic material, and promotes epithelial cell migration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-Mesitran.